Publications by authors named "E Mattarucchi"
Article Synopsis
- Imatinib mesylate (IM) is the main treatment for Chronic Myeloid Leukemia (CML) and is necessary for long-term survival, but stopping it may lead to relapse.
- Traditional tests for checking minimal residual disease are not very sensitive, but a new genomic DNA Q-PCR assay has been developed to more accurately detect the presence of leukemic cells.
- In a study of 8 CML patients on IM for over 8 years, the new gDNA Q-PCR method revealed persistent leukemic cells in nearly one-third of cases where traditional mRNA tests showed undetectable levels, suggesting it could improve decision-making for treatment.
Biomarker selection through the metabolomics approach involves the acquisition of nontargeted metabolic profiles. In this study, some critical factors that may affect this process were investigated using urine test samples and a UPLC-TOF system. Repeated injections of a single sample demonstrated that the percentage of undetected and poorly repeatable measurements (intensity RSD > 15%) decreased from 22.
View Article and Find Full Text PDF